Biogen, Inc. (NASDAQ: BGEN) today announced that Thomas Bucknum, Esq. has been appointed Executive Vice President and General Counsel. Mr. Bucknum reports to James C. Mullen, President and Chief Operating Officer.
Mr. Bucknum joined Biogen in 1996 after a 20 year career with DuPont and DuPont Merck Pharmaceuticals, where he served in diverse management roles in legal, government and public affairs, international, marketing, and regulatory affairs. He was named Biogen’s Vice President and General Counsel in 1999.
In his position as Executive Vice President, Mr. Bucknum will oversee Legal, Government and Public Affairs functions worldwide.
Mr. Mullen said, “Tom Bucknum has made considerable contributions to Biogen since joining the company six years ago. His broad management and industry experience will be of great value as Biogen grows into a multi-product global organization.”
Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from international sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen’s research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s Homepage on the World Wide Web at http://www.biogen.com.